Thornton-Cleveleys, United Kingdom
Thornton-Cleveleys, United Kingdom

Time filter

Source Type

Receive press releases from IQ4I Research & Consultancy Pvt. Ltd.: By Email IQ4I Research & Consultancy Published a New Report on "Implantable Biomaterials Global Market – Forecast to 2022" A biomaterial may be natural or synthetically derived substance intended to interface with biological systems to evaluate, treat, augment, or replace any tissue, organ, or function of the body for a life time. The increasing aging population, demand for minimally invasive surgery, R&D, miniaturized implant is driving growth. Boston, MA, December 21, 2016 --( The increasing aging population, increasing demand for minimally invasive procedures, increasing research and development investments, growing demand for plastic surgery, miniaturization of implant devices, advance technologies and reimbursements are the factors driving the biomaterials global market. However, limitations of biomaterial based products, stringent regulations posed on biomaterial based products, complications due to implant rejection, cytotoxicity, and corrosion of biomaterials implant are restraining the growth of biomaterials global market. Advancements and newer technologies like 3D printing are revolutionizing implantable biomaterials market. 3D Printing promises to produce complex biomedical devices using computer design based on patient-specific anatomical data. Before 3D Printing can be used routinely for the regeneration of complex tissues (e.g. bone, cartilage, muscles, vessels, nerves in the craniomaxillofacial complex), and complex organs with intricate 3D microarchitecture (e.g. liver, lymphoid organs). The commonly used 3D printing technologies are Fused Deposition Modeling, Selective Laser Sintering, Stereolithography, and 3D Plotting/Direct-Write/ Bioprinting. With the increase in 3D printing technology better and anatomically accurate implants can be manufactured which directly affects the consumption of biomaterials by medical implants manufacturing companies. A leading advanced materials and 3D printing company, Oxford Performance Materials, Inc. (OPM), has announced that it has received 510(k) clearance from the US Food & Drug Administration (FDA) for its 3D printed OsteoFab Patient-Specific Facial Device. Currently, it is the only cleared 3D printed polymeric implant for facial indications of its kind, although it is not completely new territory for OPM as the company previously got FDA clearance for another kind of 3D printed medical implant in February 2013. Amedia Corporation is the first company to create medical silicon nitride ceramics using a 3D printing process called robotic deposition, or robocasting. The 3D printed products have been shown to possess similar properties to traditionally manufactured alternatives. In February 2016 BioArchitects received 510(k) clearance by the U.S. Food and Drug Administration – FDA, for the company’s 3D printed patient specific titanium cranial/craniofacial plate implant. Designed for the repair of defects in the non-loadbearing bones of the head and face, each custom designed plate is permanently attached to the skull and/or face with self-tapping titanium screws. The implantable biomaterials global market is segmented based on type, application, and geography. The market by type is divided into Metallic biomaterials, Synthetic polymers, Ceramic biomaterials, Natural biomaterials and Composite biomaterials. The implantable biomaterials application is further sub-segmented into Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Ophthalmology, Neurology and Other Applications. The Orthopedic occupied highest market in implantable biomaterials application market. Geographically, North American regions held the largest market share and U.S. dominates the North American region with market share of 79.2% and expected to show a CAGR due to the high advanced healthcare facilities, increasing ageing population, increased growing awareness about the technological advancements, availability of Medicare and third party insurance facilities, easy availability of skilled personnel are driving the market growth. In Asia-Pacific region Japan dominates the biomaterials market with share of 30.7% and expected to grow at a strong CAGR due to high levels of healthcare expenditure and a massive elderly population, technological advancements and reimbursement by Japan’s National Health Insurance (NHI) system are the major factors contributing the biomaterials market in Japan. Japan has world’s largest and fastest rates of aging population in the world which results in high rates of orthopedic, dental, ophthalmology and cardiovascular disorders. In Rest of the World regions Latin America countries especially Brazil dominates the implantable biomaterials market with share of 50.7% and is expected to grow at the strong rate due to The growth in this market is mainly due to the high acceptance of technological advancements, Medicare facilities, sophisticated infrastructure related to healthcare and high expenditure and mainly the easy availability of skilled personnel and treatment style has led the Brazil as the dominant region of biomaterials market. Some of the prominent players in implantable biomaterials market include Solvay Advanced Polymers, LLC (Belgium), Evonik Industries AG (Germany), Carpenter Technology Corporation (U.S.), Royal DSM (Netherlands), Johnson Matthey Plc (U.K.), Morgan Advanced Materials plc (U.K.), Materion (U.S.), Victrex PLC (Invibio Biomaterial Solutions) (U.K.) and Collagen solutions (U.K.), Corbion N.V. (Netherlands), Landec Corporation (U.S.). Boston, MA, December 21, 2016 --( PR.com )-- A biomaterial is a substance intended to interface with biological systems to evaluate, treat, augment, or replace any tissue, organ, or function of the body for a life time, such as total hip replacements, as well as those that interact with the body for short periods of time, such as soft contact lenses. The source of biomaterials can be derived from natural or synthetic by variety of processes laboratory using metallic, ceramic, polymer, natural and composite raw materials. The selection of biomaterial is dependent on the application and properties of materials. Biomaterials are used to develop and manufacture implantable medical devices and grafts in many medical conditions. As estimated by IQ4I Research, implantable biomaterials global market is expected to grow at a strong CAGR to reach $21,124.2 million by 2022.The increasing aging population, increasing demand for minimally invasive procedures, increasing research and development investments, growing demand for plastic surgery, miniaturization of implant devices, advance technologies and reimbursements are the factors driving the biomaterials global market. However, limitations of biomaterial based products, stringent regulations posed on biomaterial based products, complications due to implant rejection, cytotoxicity, and corrosion of biomaterials implant are restraining the growth of biomaterials global market.Advancements and newer technologies like 3D printing are revolutionizing implantable biomaterials market. 3D Printing promises to produce complex biomedical devices using computer design based on patient-specific anatomical data. Before 3D Printing can be used routinely for the regeneration of complex tissues (e.g. bone, cartilage, muscles, vessels, nerves in the craniomaxillofacial complex), and complex organs with intricate 3D microarchitecture (e.g. liver, lymphoid organs). The commonly used 3D printing technologies are Fused Deposition Modeling, Selective Laser Sintering, Stereolithography, and 3D Plotting/Direct-Write/ Bioprinting. With the increase in 3D printing technology better and anatomically accurate implants can be manufactured which directly affects the consumption of biomaterials by medical implants manufacturing companies.A leading advanced materials and 3D printing company, Oxford Performance Materials, Inc. (OPM), has announced that it has received 510(k) clearance from the US Food & Drug Administration (FDA) for its 3D printed OsteoFab Patient-Specific Facial Device. Currently, it is the only cleared 3D printed polymeric implant for facial indications of its kind, although it is not completely new territory for OPM as the company previously got FDA clearance for another kind of 3D printed medical implant in February 2013.Amedia Corporation is the first company to create medical silicon nitride ceramics using a 3D printing process called robotic deposition, or robocasting. The 3D printed products have been shown to possess similar properties to traditionally manufactured alternatives.In February 2016 BioArchitects received 510(k) clearance by the U.S. Food and Drug Administration – FDA, for the company’s 3D printed patient specific titanium cranial/craniofacial plate implant. Designed for the repair of defects in the non-loadbearing bones of the head and face, each custom designed plate is permanently attached to the skull and/or face with self-tapping titanium screws.The implantable biomaterials global market is segmented based on type, application, and geography. The market by type is divided into Metallic biomaterials, Synthetic polymers, Ceramic biomaterials, Natural biomaterials and Composite biomaterials. The implantable biomaterials application is further sub-segmented into Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Ophthalmology, Neurology and Other Applications. The Orthopedic occupied highest market in implantable biomaterials application market.Geographically, North American regions held the largest market share and U.S. dominates the North American region with market share of 79.2% and expected to show a CAGR due to the high advanced healthcare facilities, increasing ageing population, increased growing awareness about the technological advancements, availability of Medicare and third party insurance facilities, easy availability of skilled personnel are driving the market growth. In Asia-Pacific region Japan dominates the biomaterials market with share of 30.7% and expected to grow at a strong CAGR due to high levels of healthcare expenditure and a massive elderly population, technological advancements and reimbursement by Japan’s National Health Insurance (NHI) system are the major factors contributing the biomaterials market in Japan. Japan has world’s largest and fastest rates of aging population in the world which results in high rates of orthopedic, dental, ophthalmology and cardiovascular disorders. In Rest of the World regions Latin America countries especially Brazil dominates the implantable biomaterials market with share of 50.7% and is expected to grow at the strong rate due to The growth in this market is mainly due to the high acceptance of technological advancements, Medicare facilities, sophisticated infrastructure related to healthcare and high expenditure and mainly the easy availability of skilled personnel and treatment style has led the Brazil as the dominant region of biomaterials market.Some of the prominent players in implantable biomaterials market include Solvay Advanced Polymers, LLC (Belgium), Evonik Industries AG (Germany), Carpenter Technology Corporation (U.S.), Royal DSM (Netherlands), Johnson Matthey Plc (U.K.), Morgan Advanced Materials plc (U.K.), Materion (U.S.), Victrex PLC (Invibio Biomaterial Solutions) (U.K.) and Collagen solutions (U.K.), Corbion N.V. (Netherlands), Landec Corporation (U.S.). Click here to view the list of recent Press Releases from IQ4I Research & Consultancy Pvt. Ltd.


News Article | February 15, 2017
Site: www.prweb.com

Early clinical results presented by surgeons at the 2016 annual meeting of the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 months and beneficial clinical outcomes, for patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance polymer, from Invibio Biomaterial Solutions, uniquely combines PEEK-OPTIMA, the principal PEEK-based biomaterial with over 15 years of proven history in clinical use, and hydroxyapatite (HA), a well-known osteoconductive material that enhances bone apposition, and is fully integrated. Previous studies by Invibio have highlighted that enhancing bone apposition on all surfaces of an interbody-fusion device may offer better integration and improved potential for spinal fusion. “The findings on first clinical cases for PEEK-OPTIMA HA Enhanced presented at the NASS 2016 annual meeting are demonstrating the Invibio goal of providing solutions that have the potential to improve clinical outcomes and advance bone apposition in interbody-fusion procedures2,” said John Devine, Invibio Medical Business Director. “In addition, the results presented confirm that the partnerships we have forged with device manufacturers and surgeons are pioneering approaches that are leading to positive results for patients.” During NASS, Timothy Bassett, MD, of SouthEastern Spine Specialists, Tuscaloosa, AL, presented his ‘Early Clinical Experience with a PEEK-OPTIMA HA Enhanced Device for Lumbar Fusion’. The 1-2 level TLIF (Transforaminal Lumbar Interbody Fusion) procedure utilized the EVOS HA Device, from Cutting Edge Spine, intended for use in skeletally mature patients with Degenerative Disc Disease (DDD) of the lumbar spine, plus autograft bone with posterior instrumentation. No biologics were used in this series of nine patients. The clinical results were evaluated for pain on the Visual Analogue Scale (VAS), opiate usage, neurological function, re-operations and complications. Fusion results were evaluated using anteroposterior (AP) and lateral X-rays at six weeks and 12 weeks, and a CT scan at six months. Dr Bassett concluded, “Very rapid visible bone fusion occurred in the interbody region in six weeks, according to plain radiographs, with correspondingly good clinical results including no neurologic consequences beyond 6 weeks, no implant migrations, no subsidence, and no pseudoarthroses. More importantly, 9/10 fusions were definitively solid on 6 month CT scan with autograft bone, despite some challenging patients. The one that didn’t show complete fusion was progressing to fusion and used one pack of tobacco daily, both pre- and post-operative, contributing to the fusion challenge. Brad Prybis, MD at Carrollton Orthopaedic Clinic, Carrollton, GA, assessed use of the Talos®-C (HA) Cervical Interbody Fusion Device, from Meditech Spine, in patients who underwent 2-3 level anterior cervical discectomy and fusion (ACDF). Clinical (pain and neurological function) and radiographic outcomes were assessed at six months post-operatively. Arm pain was resolved in all 8 patients; in 5/8 patients neck pain was resolved and improved in 7/8 patients. Furthermore, all 8 patients demonstrated improved neurological function, with residual numbness in 3/8, and residual weakness in 1/8 patients. 17/17 levels were fused 6 months post-operatively. Commenting on the findings, Dr Prybis said, “The Talos-C (HA), a next-generation interbody-fusion device made from PEEK-OPTIMA HA Enhanced polymer, provided clinical and radiographic results as good as or better than traditional PEEK interbody devices, with consistently good outcomes at early time points we are looking forward to the results of further clinical studies.” PEEK-OPTIMA HA Enhanced biomaterial offers all the clinical advantages of PEEK-OPTIMA Natural including a modulus similar to cortical bone, reduced stress shielding and artifact-free imaging that allows for clear fusion assessment. Developed by Invibio, a leading provider of biomaterial solutions, this innovative high performance polymer for spinal fusion implants eliminates the extra processing time and expense of alternative bone on-growth technologies, such as coatings. Implant devices made of the novel PEEK-OPTIMA HA Enhanced have already been cleared by regulatory bodies in both the US (FDA 510(k) clearance) and Europe (CE mark approval). For more information about PEEK-OPTIMA HA Enhanced, please visit http://www.invibiospine.com 2. Study evaluated the in vivo response to PEEK-OPTIMA Natural, PEEK-OPTIMA HA Enhanced and allograft in a cervical spine fusion model in sheep. Data are on file at Invibio. This has not been correlated with human clinical experience. The case study data and testimonials presented here have been provided by practicing orthopedic surgeons. Their views and experiences are their own and do not necessarily reflect those of others. “Invibio” disclaims any liabilities or loss in connection with the information herein. INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. About Invibio Biomaterial Solutions Invibio, a Victrex plc company, is a global leader in providing high performance biomaterial solutions to medical device manufacturers. The company provides PEEK-OPTIMA™ polymers, advanced technical research and support and manufacturing of components for spine, trauma and orthopaedic medical segments for the development of long implantable medical devices. Today, Invibio’s PEEK-OPTIMA™ polymers are used in more than five million implanted devices worldwide. About Victrex Victrex, headquartered in the UK, is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years’ experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at http://www.victrexplc.com


News Article | October 29, 2016
Site: www.prweb.com

In July of this year, Meditech Spine received its US Federal Drug Administration (FDA) 510(k) clearance to market the next generation of cervical plates to complement its Talos®-C (HA) line of interbody devices. The CURE Anterior Cervical Plate (ACP) allows surgeons to utilize the cervical plating system along with its novel cervical interbody fusion device, cleared in 2015, which is manufactured with the PEEK-OPTIMA™ HA Enhanced polymer offered by Invibio Biomaterial Solutions. PEEK-OPTIMA HA Enhanced is a novel material for interbody fusion devices. Hydroxyapatite (HA), a well-known osteoconductive material that enhances bone apposition, is fully integrated, not coated, into the PEEK-OPTIMA matrix, making it available on all surfaces of a finished device. When a cervical disc wears out and loses height it can compress on nerves, causing neck pain, arm pain, and numbness or tingling in the arms and hands. These are common symptoms of Degenerative Disc Disease (DDD). A cervical decompression and fusion may help relieve the symptoms of DDD in the neck. It is estimated that over 300,000 cervical fusions are performed each year in the United States. The CURE ACP is the newest product offered by Meditech Spine to treat patients who need an anterior cervical fusion. The CURE ACP is a titanium plate that incorporates a unique, patent pending, one-step locking mechanism to prevent screws anchored on the spine from loosening and backing out. It is also designed with a large graft window and streamlined instruments to make it easier on hospital and surgery centers to process the system. The CURE ACP System is intended for anterior screw fixation to the C2 to C7 levels of the cervical spine. The cages are intended for use in skeletally mature patients with Degenerative Disc Disease (DDD) of the cervical spine at one level from C2-T1. Meditech’s philosophy of giving back led to a partnership with CURE International, the namesake of the CURE ACP, an organization that serves children with physical disabilities in underserved areas of the world. A portion of proceeds from the sale of every plate will help CURE International treat patients in underserved areas who are in need of surgical care. Brad Prybis, M.D., a board-certified spine surgeon, and co-developer of the CURE ACP System, performed the first procedure with the CURE ACP in Carrolton, GA. With over 3,000 attendees, Dr. Prybis will be presenting his experience using the Talos®-C (HA) Cervical IBF device at the annual North American Spine Society (NASS), meeting in Boston, MA. Presentations will take place from 10:00 to 10:30 am and 3:05 to 3:30pm on Wednesday, October 26th, in Invibio’s booth #831. Invibio demonstrated its PEEK-OPTIMA HA Enhanced polymer performance in pre-clinical studies, with greater new bone formation and higher quality of new bone bridging compared with PEEK-OPTIMA Natural at early time points.1 A previous study that evaluated the bone on-growth of the two implantable polymers in a bone defect model in sheep, revealed that PEEK-OPTIMA HA Enhanced resulted in approximately 75% direct bone apposition as early as four weeks following implantation.2 References 1. Study evaluated the in vivo response to PEEK-OPTIMA Natural, PEEK-OPTIMA HA Enhanced and allograft in a cervical spine fusion model in sheep. Data on file at Invibio. This has not been correlated with Human clinical experience. Study did not use Meditech Spine products. 2. Study evaluated the in vivo response to PEEK-OPTIMA Natural and PEEK-OPTIMA HA Enhanced in a large animal model. Data on file at Invibio. This has not been correlated with human clinical experience. Study did not use Meditech Spine products.


Hallab N.J.,Rush University Medical Center | Hallab N.J.,BioEngineering Solutions Inc. | McAllister K.,Rush University Medical Center | Brady M.,Invibio Biomaterial Solutions | Jarman-Smith M.,Invibio Biomaterial Solutions
Journal of Biomedical Materials Research - Part B Applied Biomaterials | Year: 2012

Biologic reactivity to orthopedic implant debris is generally the main determinant of long-term clinical performance where released polymeric particles of Ultra-high molecular weight polyethylene (UHMWPE) remain the most prevalent debris generated from metal-on-polymer bearing total joint arthroplasties. Polymeric alternatives to UHMWPE such as polyetherether-ketone (PEEK) may have increased wear resistance but the bioreactivity of PEEK-OPTIMA particles on peri-implant inflammation remains largely uncharacterized. We evaluated human monocyte/macrophage responses (THP-1s and primary human) when challenged by PEEK-OPTIMA, UHMWPE, and X-UHMWPE particles of three particle sizes (0.7 um, 2 um, and 10 um) at a dose of 20 particles-per-cell at 24- and 48-h time points. Macrophage responses were measured using cytotoxicity assays, viability assays, proliferation assays and cytokine analysis (IL-1b, IL-6, IL-8, MCP-1, and TNF-α). In general, there were no significant differences between PEEK-OPTIMA, UHMWPE, and X-UHMWPE particles on macrophage viability or proliferation. However, macrophages demonstrated greater cytotoxicity responses to UHMWPE and X-UHMWPE than to PEEK-OPTIMA at 24 and 48 h, where 0.7 μm-UHMWPE particles produced the highest amount of cytotoxicity. Particles of X-UHMWPE more than PEEK-OPTIMA and UHMWPE induced IL-1β, IL-6, MCP-1, and TNF-α at 24 h, p < 0.05 (no significant differences at 48 h). On average, cytokine production was more adversely affected by larger 10 μm particles than by 0.7 and 2 μm sized particles. While limitations of in vitro analysis apply to this study, PEEK-OPTIMA particles were more biocompatible than UHMWPE particles, in that they induced less inflammatory cytokine responses and thus, in part, demonstrates that PEEK-OPTIMA implant debris does not represent an increased inflammatory risk over that of UHMWPE. © 2011 Wiley Periodicals, Inc.


Berretta S.,University of Exeter | Ghita O.,University of Exeter | Evans K.E.,University of Exeter | Anderson A.,Invibio Biomaterial Solutions | Newman C.,Invibio Biomaterial Solutions
High Value Manufacturing: Advanced Research in Virtual and Rapid Prototyping - Proceedings of the 6th International Conference on Advanced Research and Rapid Prototyping, VR@P 2013 | Year: 2014

This paper investigates the effects of particles size and morphology on flowability of a range of polymeric powders (SLS and non-SLS grades). The effect of additives incorporation, as well as drying or sieving, on the flowability characteristics of the powders is also analyzed. The results show that the particle morphology has a stronger influence on the flowability than the particle size distribution. Moreover, the incorporation of additives has to be carefully considered in order to have positive effects on the powder flowability. © 2014 Taylor & Francis Group.


Hallmann L.,University of Zürich | Mehl A.,University of Zürich | Sereno N.,Invibio Biomaterial Solutions | Hammerle C.H.F.,University of Zürich
Applied Surface Science | Year: 2012

The purpose of this in vitro study was the evaluation of the bond strength of the adhesives/composite resin to Poly Ether Ether Ketone (PEEK) based dental polymer after using different surface conditioning methods. PEEK blanks were cut into discs. All disc specimens were polished with 800 grit SiC paper and divided into 6 main groups. Main groups were divided into 2 subgroups. The main groups of 32 specimens each were treated as follow: (1) control specimens (no treatment), (2) piranha solution etching, (3) abraded with 50 μm alumina particles and chemical etching, (4) abraded with 110 μm alumina particles and chemical etching, (5) abraded with 30 μm silica-coated alumina particles and chemical etching, (6) abraded with 110 μm silica-coated alumina particles and chemical etching. Plexiglas tubes filled with a composite resin (RelyX Unicem) were bonded to the specimens. The adhesives used were Heliobond and Clearfil Ceramic Primer. Each specimen was stored in distilled water (37 °C) for 3 days. Tensile bond strength was measured in a universal testing machine and failure methods were evaluated. Abraded surface with 50 μm alumina particles followed by etching with piranha solution lead to the highest bond strength of 21.4 MPa when Heliobond like adhesive was used. Tribochemical silica coated/etched PEEK surfaces did not have an effect on the bond strength. Non-treated PEEK surface was not able to establish a bond with composite resin. The proper choice of adhesive/composite resin system leads to a strong bond. Conclusion: Airborne particle abrasion in combination with piranha solution etching improves the adhesive properties of PEEK. © 2012 Elsevier B.V.


Poulsson A.H.C.,AO Research Institute Davos | Eglin D.,AO Research Institute Davos | Zeiter S.,AO Research Institute Davos | Camenisch K.,AO Research Institute Davos | And 5 more authors.
Biomaterials | Year: 2014

Machined and injection moulded polyetheretherketone (PEEK) implants with and without an oxygen plasma modification were prepared and implanted in sheep cancellous and cortical bone. After 4, 12 and 26 weeks, osseointegration was evaluated through mechanical push-out tests and histomorphometry. In the cancellous bone, push-out force increased with time, a trend toward higher force was observed for machined compared to moulded, and oxygen plasma modified compared to unmodified. On-going remodelling of the bone was detected in the periphery of the implants at 4 weeks. Minimal or no inflammation was observed with all the implants at all locations and time-points. Bone-implant contact (BIC) was quantified at all-time points and locations for all the four PEEK implant surfaces. The BIC values ranged from 15 to 75% with an average of 29±13% in the cancellous bone and 25-65% with an average of 50±12% in the cortical bone. In the cortical bone the BIC increased significantly from 4 to 26 weeks. This invivo study has identified that surface topography of PEEK implants influences osseointegration. In addition, oxygen plasma has the potential to increase bone-implant interface stability. This study provides a unique reference for further modifications and invivo assessment of PEEK implants. © 2014 Elsevier Ltd.


News Article | December 16, 2015
Site: www.materialstoday.com

Victrex has announced that it will build a new PEEK composite facility for unidirectional (UD) tape and add new manufacturing capability for medical Trauma plate applications at its U.K. headquarters. Unidirectional (UD) tape is being used for Victrex’s partnership with Magma, an oil and gas ‘mega-program’ that focuses on m-pipe. Magma´s m-pipe is a high strength polymer carbon pipe which is reportedly 90% lighter than steel in water, is stronger than steel, and has a number of performance benefits, including being highly durable, corrosion resistant to seawater, CO2 and sour gas. Victrex’s UD tape composites are also being used in aerospace applications. In trauma, Victrex will continue to invest in specific downstream manufacturing facilities during 2016. Trauma plates composed of the high-performance composite, PEEK-OPTIMA Ultra Reinforced, will be delivered by Victrex´s medical division Invibio Biomaterial Solutions (Invibio). According to the company, the plates offer 50 times better fatigue resistance compared to metal, x-ray translucency to facilitate improved fracture repair bone alignment, and stress transfer characteristics that may accelerate the healing process and address the sizeable cases of poor fracture repair or device failures that can occur in metal-based solutions. The new facility is due to start construction in early 2016.

Loading Invibio Biomaterial Solutions collaborators
Loading Invibio Biomaterial Solutions collaborators